You have accessJournal of UrologyAdrenal1 Apr 2016MP12-14 A META-ANALYSIS OF THE ROLE OF ADJUVANT RADIOTHERAPY AFTER SURGERY FOR ADRENOCORTICAL CARCINOMA Victor Srougi, Jose Bessa, Fabio Tanno, Amanda Ferreira, Lia Lousada, Madson Almeida, Cristiane Almeda, Miguel Srougi, Berenice Mendonça, Ana Hoff, Jose Chambo, and Maria Fragoso Victor SrougiVictor Srougi More articles by this author , Jose BessaJose Bessa More articles by this author , Fabio TannoFabio Tanno More articles by this author , Amanda FerreiraAmanda Ferreira More articles by this author , Lia LousadaLia Lousada More articles by this author , Madson AlmeidaMadson Almeida More articles by this author , Cristiane AlmedaCristiane Almeda More articles by this author , Miguel SrougiMiguel Srougi More articles by this author , Berenice MendonçaBerenice Mendonça More articles by this author , Ana HoffAna Hoff More articles by this author , Jose ChamboJose Chambo More articles by this author , and Maria FragosoMaria Fragoso More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2016.02.2454AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Adrenocortical carcinoma is a rare and aggressive neoplasm that often requires multimodal treatment, including adjuvant radiotherapy (ARDT). Nevertheless, because of the low prevalence of these tumors, there is scarce evidence in the literature regarding the beneficial role of ARDT in this setting. In order to clarify this controversy, we performed a systematic review and meta-analysis of the available studies addressing the use of adjuvant radiotherapy following excision of adrenal cortex cancer. METHODS A systematic review was performed in Medline, Cochrane and Scopus databases searching for words related to adrenocortical cancer and radiotherapy in English language. There was no time limitation. We selected articles that compared patients bearing adrenocortical cancer treated with surgery alone and patients that had primary surgical treatment followed by ARDT. The endpoint was local tumor recurrence. Articles that addressed the use of radiotherapy for local recurrence, for metastasis and as the primary treatment of adrenocortical cancer were excluded. RESULTS A total of 15 studies were found, of which four met the inclusion criteria. All the four articles were retrospective and the median follow-up was 35,5 months (range: 34–72 months). Among the selected studies, 104 patients had surgery alone as primary treatment and 60 patients had surgery followed by ARDT. The median post-operative radiation dose in the selected studies ranged from 50,4 to 55 Gys. Meta-analysis for local recurrence showed that the use of ARDT after surgery was associated with lower risk of local cancer recurrence (OR = 0.36; 95% CI=0.156 – 0.812; p = 0.014). CONCLUSIONS Despite the absence of high-level clinical studies, our result supports the use of adjuvant radiotherapy for surgically treated adrenocortical carcinoma. When intending to provide the best cure possibility for these patients and until well-designed prospective studies become available, ARDT should be considered in this clinical setting. © 2016FiguresReferencesRelatedDetails Volume 195Issue 4SApril 2016Page: e131 Advertisement Copyright & Permissions© 2016MetricsAuthor Information Victor Srougi More articles by this author Jose Bessa More articles by this author Fabio Tanno More articles by this author Amanda Ferreira More articles by this author Lia Lousada More articles by this author Madson Almeida More articles by this author Cristiane Almeda More articles by this author Miguel Srougi More articles by this author Berenice Mendonça More articles by this author Ana Hoff More articles by this author Jose Chambo More articles by this author Maria Fragoso More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...